Il progetto, curato da Monica Preti, direttrice generale di Fondazione Pistoia Musei, e Annamaria Iacuzzi, conservatrice delle collezioni del Novecento, con la collaborazione dell’Archivio Carol Rama, presenta sette opere dell’artista torinese, provenienti dalle Collezioni Gallerie d’Italia – Intesa Sanpaolo e da una collezione privata. Si tratta di una serie di dipinti rappresentativi dell’evoluzione creativa di Carol Rama, realizzati tra l’inizio degli anni Cinquanta e la prima metà degli anni Settanta. Opere che consentono un approfondimento su fasi meno note del percorso dell’artista: dal periodo di adesione all’astrazione con il Movimento Arte Concreta (MAC) degli anni Cinquanta, allo sviluppo di una originale poetica informale con i “Bricolages” dove associa alla macchia oggetti di scarto carichi di vissuto nei Sessanta; dalle sperimentazioni con le camere d’aria di bicicletta nelle “Gomme” della serie Luogo e segni, ai lavori con filo cucito su stoffa dei ‘diagrammi’ nei primi anni Settanta.

In Visita è un progetto di Fondazione Pistoia Musei, realizzato con il supporto di Fondazione Caript e con la partnership di Intesa Sanpaolo e il sostegno delle aziende della Corporate Membership di Pistoia Musei.

Accompagna l’iniziativa un volume edito da Gli Ori-Pistoia con interventi Monica Preti e Annamaria Iacuzzi e un pregevole contributo critico di Maria Grazia Messina.

AMSTERDAM, Oct. 1, 2026 /PRNewswire/ — FORCYD today announced its expansion into Switzerland with the opening of a new office in Zurich and the appointment of Bob Dillen as Partner leading the firm’s Swiss practice. 

Over recent years, FORCYD has built a reputation as Europe’s premier eDiscovery, Investigations, and Cyber Forensics consultancies, growing from our Amsterdam origins to offices in Brussels, London, Frankfurt, Paris and Madrid. The relationships and standards we have developed reflect our core commitment to quality and client service. 

The opening of our Zurich office enhances our ability to support clients locally in the DACH region while continuing to deliver cross-border expertise in complex legal and regulatory matters. The new office reflects the growing demand for specialist expertise in managing digital information across litigation, investigations, regulatory proceedings and other complex matters. 

Bob Dillen brings more than two decades of international experience in forensic technology, eDiscovery and investigations, having advised organisations on arbitrational and dispute cases, regulatory matters and large-scale global investigations across multiple sectors. 

Bas Sluijsmans, Partner and co-founder of FORCYD, comments: 

“We are delighted to welcome Bob to FORCYD and to open our new office in Zurich. Bob is highly regarded in the market and brings decades of experience helping organisations navigate investigations, litigation and regulatory challenges. Just as importantly, we share the same commitment to quality, independence and client service. Bob will play a key role in our continued growth, and we look forward to building our Swiss practice and our global investigations offering together.”  

Bob Dillen adds: 

“Having spent my career helping organisations navigate complex investigations, disputes and regulatory matters, I have seen first-hand the value of combining specialist expertise with a practical, hands-on approach. FORCYD shares that mindset, and I am delighted to join the firm and lead its Swiss practice.” 

About FORCYD 

FORCYD offers high-end eDiscovery, cyber forensic and investigation advisory services and solutions. As an independent, globally operating consultancy with offices across Europe, FORCYD helps organisations and their advisers establish the facts and respond with confidence in matters involving misconduct, litigation, data breaches and other complex legal and regulatory challenges. We are called upon when the stakes are high, the matters complex, cross-border and time is of the essence, a trusted advisor to our clients and their legal counsels. 

View original content:https://www.prnewswire.co.uk/news-releases/forcyd-expands-into-switzerland-and-appoints-bob-dillen-as-partner-to-lead-swiss-practice-302894824.html
 

Copyright 2026 PR Newswire. All Rights Reserved. 

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE: Immediapress è un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. L’Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi

—

immediapress/pr-newswire

Family-Owned Brand Brings Single-Source Organic Tequila to New Shores 

ST. HELENA, Calif., Oct. 1, 2026 /PRNewswire/ — Tres Agaves Tequila, the family-owned, 100% de Agave producer from Mexico’s Tequila Valley, is launching in the UK and Ireland on October 1st, its first move into the European on-premise and independent retail trade. The rollout continues into Germany, Switzerland, the Nordics and Spain in the months that follow, with a formal European trade introduction at Bar Convent Berlin in mid-October. 

Tres Agaves distills every drop from a single source in Amatitán, the birthplace of Tequila, built on nearly two decades of direct relationships with local growers. That single-estate sourcing, paired with USDA and Mexican organic certification and NOM-registered production, has made the brand a fixture behind U.S. bars. The UK and Ireland launch brings the same proposition to European bartenders and independent retailers for the first time. 

“Tequila is one of the fastest-growing spirits categories in Europe, and bartenders want brands with real provenance,” said Thomas Vogele, Vice President International Sales for Trinchero Family Wine & Spirits. “Tres Agaves gives the trade an organic, single-source Tequila from a genuinely family-owned producer, at a price accessible for the back bar rather than the top shelf.” 

The European Tequila market is set to reach a revenue of $2.49 billion by 2030, with a compound annual growth rate of 9.6% between 2025 and 2030. Tres Agaves is up +769% FYTD in the Trinchero Export Division. ¹ Stateside, Tres Agaves was recently named to Shanken’s Impact 2026 “Hot Prospects” list, recognizing it among the fastest-growing spirits brands in the U.S.² Against this backdrop of growth, Tres Agaves is thrilled to offer its organic Tequila range to bartenders and consumers in the UK and Ireland and bring even more momentum to this vibrant category. 

Launching in the UK & Ireland: 

Blanco and Reposado launch in a 700 ml pack size to meet European market requirements with suggested retail pricing ranging from £40-£45. Tres Agaves is exported by Trinchero Family Wine & Spirits. 

¹ Source: Circana, Total MULO + with Conv + LIQ; L26wks ending 8/03/26 

² Source: Shanken News Daily, “Exclusive: RTDs, Tequila Drive Lead Impact’s ‘Hot Prospects’ List,” September 14, 2026. 

About Tres AgavesTres Agaves produces award-winning 100 percent de Agave Tequilas and USDA Organic cocktail mixers. Tres Agaves Tequilas are produced in the Tequila Valley using time-honored traditions. Its mixers are USDA certified organic, gluten-free and sweetened only with the finest blue weber agave nectar, making them the perfect choice for health and calorie conscious consumers. Tres Agaves cocktail-ready agave nectar, lime margarita, strawberry margarita, and Bloody Mary mixers were carefully formulated to help people make the most delicious cocktails possible by enhancing rather than overwhelming the flavors of high-quality Tequila. Visit www.tresagaves.com to learn more. 

About Trinchero Family Wine & Spirits A family-owned company for more than 75 years, Trinchero Family Wine & Spirits comprises more than 50 award winning wine and spirits brands distributed globally. Founded in 1948 – when Italian immigrants Mario and Mary Trinchero moved their young family from New York City and purchased the Suter Home winery in St. Helena – Trinchero Family Wine & Spirits remains rooted in Napa Valley. From these humble beginnings Trinchero has grown to become one of the five largest US wineries through strategic partnerships and investments in technology and vineyards, all while maintaining a steadfast commitment to quality, value, sustainability and philanthropy. Learn more at www.tfewines.com. 

View original content:https://www.prnewswire.co.uk/news-releases/tres-agaves-tequila-launches-in-uk-ireland-and-continental-europe-302895175.html
 

Copyright 2026 PR Newswire. All Rights Reserved. 

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE: Immediapress è un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. L’Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi

—

immediapress/pr-newswire

Passport details are the most common source of corrections, and travelers from Singapore are the most likely to get every detail right 

NEWARK, Del., Oct. 1, 2026 /PRNewswire/ — Three in four travelers (76%) complete their electronic travel authorization correctly on the first attempt, according to the Service eVisa Travel Readiness Index. Passport details are the most common source of corrections, and travelers from Singapore are the most likely to get every detail right. 

The Travel Readiness Index measures the share of applications that needed no correction at caseworker review. It is based on more than 10,000 anonymized applications for the UK ETA, US ESTA, Canada eTA, New Zealand NZeTA and Australia ETA, submitted between January 1 and September 1, 2026. 

What are the most common travel authorization mistakes?Passport details (number, issue or expiry date) accounted for 31% of corrections, followed by name order and middle names (19%), confusion between nationality and passport issuing country (13%), and date-of-birth format (9%). 

These details matter because each authorization is linked electronically to a specific passport. On the US ESTA system, an error in passport or biographical information requires a new application and a new fee. 

Which nationalities are the most travel-ready? 

“The travelers who do best copy their details straight from the passport they will travel with, character by character,” said Fred Jordan, Director of Operations at Service eVisa. “Small details, like the order of your names or the format of a date, are where even experienced travelers slip.” 

How to get a travel authorization right the first time 

Travelers can check the requirements for each destination at serviceevisa.com. 

About Service eVisaService eVisa is a private, independent travel authorization assistance platform that helps travelers prepare and submit electronic travel authorizations for destinations including the United Kingdom, the United States, Canada, Australia and New Zealand. Applications are supported by registered migration agents and licensed immigration advisers. Service eVisa holds a travel agency license, is accredited by IATA and is a member of ASTA and PATA. Learn more at serviceevisa.com.  

Media contact: contact@serviceevisa.com
 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/three-in-four-travelers-get-their-esta-uk-eta-or-eta-right-the-first-time-service-evisa-index-finds-302891801.html
 

Copyright 2026 PR Newswire. All Rights Reserved. 

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE: Immediapress è un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. L’Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi

—

immediapress/pr-newswire

SHANGHAI, CHINA – Media OutReach Newswire – 30 September 2026 – During HUAWEI CONNECT on September 17, 2026, Eric Xu (Huawei’s Rotating Chairman) and Dr. Liao Heng (Chief Scientist of HiSilicon) had a Q&A session with journalists of media outlets to discuss Huawei’s Peerium Computing Architecture for the AI era as well as UnifiedBus (UB).
 

At last year’s HUAWEI CONNECT, Eric Xu gave a keynote speech and released Ascend chips and their roadmap (including the 950, 960, 970, and SuperPoDs and SuperClusters). He also announced the open release of the UnifiedBus protocol. 

At this year’s HUAWEI CONNECT, Huawei announced the Ascend 950 and the Atlas 950 SuperPoD. While the industry is talking about SuperPoDs or supernodes, the ways of making these products differ hugely. The key of SuperPoDs is about allowing several thousand or even tens of thousands of processors to work as one computer. 

Today, Huawei announced a SuperPoD based on the Ascend 950 chip. The SuperPoD is powered by a new computing architecture that Huawei has pioneered. This architecture now can make one million processors work as one computer. This architecture is called Peerium, and it can achieve strong scaling to the million-processor level through nested parallelism, unified memory addressing, and peer-to-peer interconnect. It extends the parallelism paradigm of Turing with the introduction of Nested BSP (Nested Bulk Synchronous Parallel). 

This architecture also extends the von Neumann single-machine architecture and overruns the master-slave design paradigm that has prevailed for decades. Given that the available technologies in the industry could not support this architecture, Huawei invented a key interconnect technology – UnifiedBus. Ultimately, one million processors can truly work as one larger computer. 

UnifiedBus is a high-speed bus that uses an open protocol to scale without a limit to connect CPUs, NPUs, memory, SSDs, interface cards, and switches. With UnifiedBus, peer-to-peer interconnect is achieved across compute, storage, and networking. This fundamentally overruns the traditional master-slave architecture. 

The Atlas 950 SuperPoD is a product built upon the Peerium Computing Architecture. A SuperCluster with 256,000 computing cards is currently being deployed and tested. 

Q: Dr. Liao, your paper mentioned a SuperPoD that’s made up of 256,000 cards. Is that the upper limit of your technology? Can you tell us more about market demand for your products?
 

Liao Heng: 256,000 or roughly 200k, this number is not an arbitrary number. 

First of all, the purpose of these large clusters is for training. It has a hardware infrastructure that can support the training of foundation models, which today are already in the 5T parameter range. 

Over the next two years, there will be roughly 6 or 7 frontier AI labs in China, and all will aim at training foundation language models of sizes ranging from 10 to 40 trillion parameters. These numbers kind of match up to the memory capacity and the size of the SuperPoD. So you need such a scale of infrastructure to train these models. 

The second thing is that in China, most data centers have a national plan on this power grid. So 200,000 is a relatively conservative number, given the design of the power delivery system in a single autonomous zone and single data center campus. 

As I said, everybody must be quite familiar with the AI model race that’s happening across the globe. And in China, there are at least 3 or 4 tier-1 players that are already well recognized and have achieved tier-1 status. 

Q: What are your plans to encourage Chinese model providers to use Ascend chips for training?
 

Eric Xu: For the Ascend 950, we first launched the 950PR to the market. It’s primarily used for AI inference, and currently the total volume of supply available in the market is not very big. The SuperPoDs based upon the Ascend 950DT are mainly used for AI training. Right now, they are under testing, and their large-scale supply will start at the end of this year or early next year. We are having extensive dialogues and discussions with AI model providers. The testing result of using the Ascend 950DT for training is pretty good. I believe that starting from next year, a lot of AI model training will be based upon SuperPoDs that use the Ascend 950DT. I think at the end of the day, it’s not about how hard we are going to push model providers, but about how much supply capacity we will have. We can only supply based on how much that’s produced. And we hope the value chain will expand its capacity faster to increase supply. 

Q: What is Huawei’s take on recent calls by leading AI model providers in the US to slow down AI development?
 

Eric Xu: We need to look at the level and cadence of AI development in China and the US. AI models in China are largely open-source models and their progress is relatively transparent. If we look at the mainstream model providers in the US, they have more computing power, so maybe only they themselves know where they are in terms of the level of sophistication of their models. The market feeling about AI risks might be weaker in China than in the US. Model providers in China need to speed up their pace to reach a level where they could also feel the risks from AI development. And then, maybe they will feel the same as the leading US model providers. But I always believe that we need to strike a balance between driving AI development and managing AI risks. At the very least, the bottom line is we need to ensure AI for good, not AI for evil. 

Q: Does Huawei have plans to bring the Atlas 950 SuperPoD to other markets outside China? If yes, which markets are you going to target? Can you share with us data about your market share in China? What is your take on China’s push for chip self-sufficiency?
 

Eric Xu: Since we don’t have enough capacity to even satisfy the demand in China, we don’t have plans to expand to the international market in a fully-fledged way. But indeed, there are several countries that have very strong demand. We are doing some testing, and we are providing some supply to those countries, but the volume is quite limited. 

Right now, it’s pretty hard to collect data about the market share of NVIDIA in China. But based on the data we have collected, Ascend has surpassed NVIDIA. 

China’s push for chip self-sufficiency is an inevitable path forward. China is a country of 1.4 billion people and it’s an industrial powerhouse, so the way people work and live is closely tied to chips. Chinese people have a keen sense of urgency, and will not accept a future in which others decide whether or not we can have access to certain products. Even though our chips may be less advanced, at least their supply is assured, so that you don’t have to worry about chip supply day in and day out. I think that’s certainly the path forward. For the Chinese government, for the domestic industry, and for Huawei, the path forward is undoubtedly to push for full self-sufficiency in terms of chips and the entire semiconductor value chain. We also believe this will become a reality sooner or later. 

To read the full Q&A session:
https://www.apmultimedianewsroom.com/multimedia-newsroom/huawei-pioneers-a-new-computing-architecture-for-the-ai-era-making-one-million-processors-work-as-one-computer-2
 

Contatti:
Immediapress
comunicati@immediapress.it

Media contact: HuaweiCorporate.comms@huawei.com  

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE

Responsabilità editoriale di Immediapress

—

immediapress

The event brings together customers, partners, and industry leaders to advance endpoint security, resilience, and secure workspace delivery. 

DUBAI, UAE, Oct. 1, 2026 /PRNewswire/ — IGEL®, a global software company delivering the IGEL Adaptive Secure Endpoint Platform™, today announced it is bringing the IGEL Now & Next® Workspace & Endpoint Security Summit to Dubai, United Arab Emirates, for a showcase on October 21, 2026, at Dubai Knowledge Park. The one-day program will bring together IT and security leaders to examine the endpoint security, resilience, and workspace delivery priorities shaping enterprise strategy across the region. 

The Dubai event extends IGEL’s flagship Now & Next® series following its five-city European roadshow earlier this year, as well as events in Australia and the United States. It arrives as organizations across the Middle East increase investment in artificial intelligence, cloud services and digital experiences, expanding the technology environments they must manage and secure. 

According to the UAE Government Cybersecurity Council, the country faces more than 90,000 to 200,000 breach attempts every day, underscoring the security pressures accompanying the region’s rapid digital transformation. As these environments become more distributed and interconnected, organizations are placing greater emphasis on strengthening cyber resilience and maintaining operational continuity while continuing to innovate. 

“What we are hearing from customers is consistent: organizations want stronger control at the endpoint, greater resilience when disruption occurs, and a practical path to support both current and emerging workspace models,” said Klaus Oestermann, CEO of IGEL. “The Now & Next® summit roadshow is designed to bring those conversations closer to home, together with the customers and ecosystem partners, helping define the next phase of endpoint strategy.” 

The summit will bring together IGEL leaders, customers, and ecosystem partners to share perspectives on secure endpoint strategy, resilience, and the future of digital work. Complementing the IGEL-led sessions, customers and ecosystem partners will bring real-world perspectives and expertise to the program, including event sponsors Microsoft, Omnissa, and Lenovo. 

“Dubai is an important meeting point for technology leaders across the Middle East, and the Now & Next® summit gives us an opportunity to bring the region’s customers, partners and experts together around the challenges they are addressing today,” said Carsten Thomsen, VP of Sales for Emerging Markets at IGEL. “The goal is to turn those conversations into practical ideas organizations can take back to their own environments.” 

The summit runs from morning sessions through the afternoon executive panel and networking lunch at Dubai Knowledge Park – Conference Centre Block 1. Attendance is open to enterprise IT and security leaders across the UAE and broader Middle East region. 

To learn more about the security, resilience and workspace modernization topics that will be explored at Now & Next® Dubai, read the latest IGEL blog. 

To review the full agenda, explore speakers, and register, visit the event page. 

About IGELIGEL® is a global software company delivering the IGEL Adaptive Secure Endpoint Platform™, a trusted and governed endpoint platform for secure access to cloud, VDI, DaaS, SaaS, Secure Browsers, enterprise applications, as well as OT endpoints. At its foundation is IGEL OS, an immutable operating system that helps reduce endpoint attack surface, preserve a known-good endpoint state, and support secure access across distributed work environments. Through the IGEL Preventative Security Model®, the platform adds attested workload delivery, centralized governance, and contextual enforcement, aligning endpoint security with Zero Trust and SSE/SASE architectures from key IGEL Ready partners. 

IGEL Business Continuity & Disaster Recovery™ (BC&DR) helps organizations restore secure access on Windows endpoints affected by ransomware, other cyberattacks, or outages. Founded in 2001, IGEL is headquartered in Germany with U.S. offices in San Francisco and Fort Lauderdale, working with an ecosystem of 130 leading technology brands. Learn more at www.igel.com. 

Windows is a trademark of the Microsoft group of companies. 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/igel-brings-now–next-workspace–endpoint-security-summit-to-dubai-302895202.html
 

Copyright 2026 PR Newswire. All Rights Reserved. 

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE: Immediapress è un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. L’Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi

—

immediapress/pr-newswire

CEAir
 

SHANGHAI, Oct. 01, 2026 (GLOBE NEWSWIRE) — China Eastern Airlines (CEAir) ha presentato i progressi nel campo delle tecnologie digitali e intelligenti nell’ambito del supporto operativo, dei servizi ai passeggeri, della manutenzione degli aeromobili e del trasporto aereo di merci in occasione della quarta edizione della CATA Aviation Conference & Exhibition, organizzata a Pechino alla fine di settembre dalla China Air Transport Association (CATA). 

È possibile consultare lo snippet a corredo di questo annuncio facendo clic sul link di seguito.
 

Presso il proprio stand espositivo, la compagnia aerea ha mostrato come l’IA viene applicata nel settore dell’aviazione civile attraverso prototipi fisici, modelli di apparecchiature, display multimediali, dimostrazioni interattive e dirette streaming. 

Un sistema flessibile a braccio robotico per la preparazione dei pasti basato sull’IA è stato uno dei fulcri di maggiori interesse della sezione dedicata al servizio di catering intelligente a bordo. I suoi dispositivi di estremità adattivi sono dotati di una flessibilità tale da afferrare e posizionare con precisione alimenti di diversi tipi e forme, consentendo la disposizione automatizzata dei pasti serviti a bordo. 

Nella sezione dedicata ai servizi intelligenti per i passeggeri sono stati esposti un robot di servizio, un robot per la movimentazione dei bagagli e un robot a quattro zampe per l’assistenza negli spostamenti, sviluppati dalla compagnia aerea e dotati di funzionalità basate su modelli di grandi dimensioni. 

La compagnia aerea ha inoltre sviluppato e presentato la propria piattaforma di gestione della rete basata sull’IA, che consente ai visitatori di visualizzare in tempo reale la posizione degli aeromobili a fusoliera larga di CEAir in tutto il mondo e dei satelliti che utilizzano per la connettività Internet in volo. 

I collegamenti aria-terra rappresentano un ambito chiave del percorso di sviluppo digitale e intelligente di CEAir. Dal luglio 2026, la compagnia aerea offre il Wi-Fi gratuito a bordo su tutti i voli operati con aeromobili a fusoliera larga, diventando così una delle prime grandi compagnie aeree al mondo a proporre il Wi-Fi a bordo come servizio standard a disposizione di tutti i passeggeri. 

Durante la mostra è stato possibile scoprire, tra gli altri aggiornamenti digitali e intelligenti, attrezzature intelligenti per la logistica della catena del freddo dei prodotti freschi, trattori autonomi per il trasporto bagagli, hangar modulari e terminali digitali. 

Anche le operazioni di CEAir relative al velivolo C919 hanno suscitato molto interesse. 

La flotta di C919 è cresciuta fino a raggiungere, ad oggi, 17 aeromobili, che operano su 23 rotte principali collegando 14 città. La flotta ha effettuato oltre 30.000 voli commerciali, trasportando più di 4 milioni di passeggeri. 

Durante la cerimonia di apertura dell’evento, il progetto di CEAir sulle tecnologie chiave per le operazioni su larga scala del C919 si è aggiudicato il secondo premio nell’ambito dei premi scientifici e tecnologici 2025 per la categoria dell’aviazione civile. 

Con una rete di rotte mondiale che copre 945 destinazioni in 145 Paesi e regioni e una flotta moderna composta da oltre 850 aeromobili, la compagnia aerea è in grado di trasportare 150 milioni di passeggeri all’anno. 

Website: http://www.ceair.com/ 

Contatto: Caowei 

E-mail: ceapr@ceair.com 

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE: Immediapress è un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. L’Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi

—

immediapress/globenewswire

SINGAPORE, Oct. 1, 2026 /PRNewswire/ — Emerald
 Clinical Trials, a leading global clinical research organization anchored in Asia-Pacific, today announced the appointment of Michael Stibilj as Chief Executive Officer, effective 1 October 2026. The appointment marks the beginning of the company’s next phase of growth. 

Michael brings over 30 years of global CRO industry experience. He joins Emerald Clinical after six years with Novotech where he was Chief Operating Officer; prior to that he was CEO at PPC Group for three years and spent 22 years with IQVIA in several regional and global leadership positions. He has helped these organizations through complex transformations, driving significant revenue growth and market leadership, with deep operational experience across Asia-Pacific, including China, Singapore and Australia. 

His appointment follows a transformative year for Emerald Clinical, including the acquisition of Hongyi Clinical Development Services. The combination created a uniquely positioned clinical development platform of more than 1,000 professionals across 40+ countries and 70+ locations, supporting sponsors from first-in-human trials through post-marketing across China, Asia-Pacific, Europe and the Americas. 

“Michael is the right leader for Emerald Clinical’s next chapter of growth,” said Sean Carney, Chairman of the Board. “He combines proven operational strength, a global perspective, and deep Asia-Pacific experience with a track record of taking businesses to the next level. On behalf of the Board, I thank Glenn Kerkhof, whose leadership as Interim CEO delivered growth and continued excellence for our customers. Glenn remains on the Board and continues to advise the company.” 

“The outlook for our industry has never been more exciting: global clinical development is on a sustained growth path as innovation pipelines expand — and Asia-Pacific is where that growth is fastest. The future of clinical research will be shaped by the application of technological advances at the intersection of global reach and Asia-Pacific depth — and no company sits more squarely at that intersection than Emerald Clinical,” said Michael Stibilj, Chief Executive Officer. “Our commitment to our people and customers is clear: high-quality delivery, speed, and transparency in everything we do. I am excited to join a team with this much momentum, and I am confident in what we will build together — a globally competitive CRO anchored in Asia-Pacific.” 

About Emerald Clinical Trials 

Emerald Clinical Trials is a global, full-service CRO with over 25 years of experience, partnering with 160+ biotechnology companies and 15 of the world’s top 20 pharmaceutical firms. Headquartered in Singapore, with 1,000+ professionals across 40+ countries and a collaborative network spanning 70+ locations, Emerald delivers end-to-end Phase I–IV and real-world solutions, with recognized scientific leadership across Renal, Oncology, Cardiometabolic, Autoimmune, Ophthalmology, and Early Phase development. In China, the company operates as Emerald Clinical 弘翼临床. For more information, visit www.emeraldclinical.
com. 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/emerald-clinical-trials-appoints-michael-stibilj-as-chief-executive-officer-to-lead-next-phase-of-global-growth-302894772.html
 

Copyright 2026 PR Newswire. All Rights Reserved. 

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE: Immediapress è un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. L’Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi

—

immediapress/pr-newswire

MIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) — MONAT Global Corp (MONAT), a global leader in naturally based haircare, skincare, and wellness products, is celebrating an extraordinary showing at the 2026 Global Green Beauty Awards, earning 14 honors across 11 products and product collections. 

With more than 800 products competing in this year’s awards, MONAT’s impressive results are a powerful testament to the brand’s commitment to combining naturally based formulations, cutting-edge science, and high-performance innovation. 

Leading the wins was REWIND™ Age Control Nectar, earning an impressive three Gold Awards for Best Vegan Serum, Best Vegan Anti-Aging Serum and Best 95%+ Natural Skincare Product.
 

MONAT’s iconic REJUVENIQE® earned Bronze for Best Vegan Hair Oil, while Double-Action Hydrating Serum received two Silver Awards for Best Vegan Hair Treatment and Best Natural Hair Treatment.
 

IR Clinical™ Hair Thinning Defense Scalp Serum receiving Silver for Best 95%+ Natural Hair Product, IR Clinical™ Thickening Shampoo earning Bronze for Best Natural Strengthening Shampoo and IR Clinical™ Thickening Conditioner earning Bronze for Best Natural Conditioner. 

Additional recognition went to MONAT SCALP COMFORT™ Rebalancing Serum, Highly Commended for Best 95%+ Natural Hair Product; Eye Smooth™ Serum, Bronze for Best Natural Eye Serum; and MONAT BLACK™ Shampoo + Conditioner, Highly Commended for Best Natural Shampoo. 

THE IR™ Supplement, available in the U.S., received Silver for Best Hair Supplement and was Highly Commended for Best 95%+ Natural Product. 

“To have so many MONAT products recognized among more than 800 entries is an incredible honor,” said Ray Urdaneta, CEO and Co-Founder of MONAT Global. “These awards celebrate what we strive for with every formula we create: uncompromising quality, meaningful innovation, and exceptional performance. We are incredibly proud to see our products recognized on a global stage.” 

The Global Green Beauty Awards recognize excellence across natural, vegan, ethical, and environmentally conscious beauty categories. MONAT’s wins reinforce the brand’s continued pursuit of premium beauty powered by nature, science, and innovation. 

About MONAT:
MONAT Global is a leading social selling brand delivering naturally based, science-backed haircare, skincare, and wellness products through a passionate community of independent Market Partners. Founded in 2014 and headquartered in Miami, FL, MONAT operates in multiple international markets and continues to expand its global footprint with integrity, innovation, and impact at its core.
 

For media inquiries, please contact: Carla Hernandez, VP, Global Marketing (305) 781-4995 CarlaH@MonatGlobal.com
 

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE: Immediapress è un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. L’Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi

—

immediapress/globenewswire

FIRENZE – Il ministro dell’interno Matteo Piantedosi ha annunciato al question time alla Camera l’avvio delle procedure per realizzare nuovi Centri di permanenza per i rimpatri (Cpr), tra cui uno in Toscana. Il governo sta lavorando anche all’attivazione di altri 106 posti in strutture già esistenti in Sicilia, Sardegna e Lazio. Le nuove strutture saranno sei in tutto: una in Campania; due in Trentino Alto Adige; una in Calabria; una in Emilia-Romagna e appunto una in Toscana.

Immediata la reazione del governatore toscano Eugenio Giani. “Ennesima iniziativa elettorale – dice – dopo il bollo, dopo l’esclusione dei bambini stranieri dalle scuole, ora la volontà di forzare sui Cpr”.

Giani entra poi nel merito dell’efficacia dei centri. “I Cpr sono un elemento di attrazione di situazioni di disagio assolutamente inefficaci per le procedure di rimpatrio, che non si attivano se non ci sono convenzioni fra l’Italia e i rispettivi paesi – aggiunge il governatore – In Toscana faremo di tutto, nel rispetto delle leggi, perché vengano impediti questi stati di detenzione impropria“.

Di segno opposto la posizione della Lega. “Esprimo piena soddisfazione per l’avvio dell’iter per sei nuovi Cpr in tutta Italia – afferma il senatore toscano Manfredi Potenti – compresa la Toscana, annunciato dal ministro Piantedosi. È una scelta di buon senso e di rigore che la Lega sostiene da sempre”.

Per Potenti i centri sono “uno strumento essenziale per rendere effettive le espulsioni e contrastare l’immigrazione clandestina”. Il senatore attacca poi il governatore. “In Toscana Giani vorrebbe il caos e si limita alle chiacchiere – sostiene – mentre il governo di centrodestra agisce con concretezza sul fenomeno migratorio. Basta ai veti della sinistra che finora hanno portato solo confusione nelle Regioni da loro amministrate. Servono centri efficienti e procedure veloci per allontanare chi non ha diritto a rimanere nel nostro paese. Tutelare i cittadini e la loro sicurezza resta per noi la cosa più importante”

REDAZIONE

MUMBAI, India, 30 settembre 2026 /PRNewswire/ — Piramal Pharma Solutions (“PPS”), un’organizzazione leader a livello globale per lo sviluppo e la produzione a contratto (CDMO) e parte di Piramal Pharma Ltd. (“PPL”) (NSE: PPLPHARMA) (BSE: 543635) ha annunciato oggi che il suo stabilimento di Aurora, in Canada, dedicato alla produzione di principi attivi farmaceutici, ha ricevuto un investimento di 1.753.620 dollari dal governo dell’Ontario attraverso il Life Sciences Scale-Up Fund (LSSUF), consentendo a PPS di potenziare le infrastrutture del sito e commercializzare tecnologie sanitarie prodotte in Ontario per nuovi mercati. 

Con il supporto del governo dell’Ontario, Piramal Pharma sta investendo 5.314.000 dollari per potenziare le infrastrutture del suo stabilimento di Aurora, rafforzando la produzione farmaceutica dell’Ontario e incrementando la produzione nazionale di principi attivi farmaceutici. Questo progetto migliorerà la ricerca e sviluppo e la produzione clinica di principi attivi farmaceutici, garantirà la disponibilità commerciale di principi attivi essenziali e sosterrà un settore delle scienze della vita resiliente e competitivo a livello globale in Ontario. L’investimento creerà 12 nuovi posti di lavoro e tutelerà 183 posizioni esistenti. 

“Siamo grati al Governo dell’Ontario e alla deputata provinciale Dawn Gallagher Murphy per il loro sostegno a questo importante investimento nel nostro stabilimento di Aurora”, ha dichiarato Peter DeYoung, CEO di Piramal Global Pharma. “Questi finanziamenti consentiranno a Piramal Pharma Solutions di ammodernare le infrastrutture del nostro sito, rafforzare le nostre capacità produttive e migliorare la nostra capacità di servire pazienti e clienti in tutto il mondo. Oltre a sostenere la crescita aziendale, questo investimento contribuirà a promuovere progetti incentrati sulla sostenibilità, l’efficienza operativa e la modernizzazione del nostro sito, rafforzando il nostro impegno per una produzione responsabile e la tutela dell’ambiente.” 

“Attraverso il Life Sciences Scale-Up Fund, il nostro governo si impegna a garantire che le imprese dell’Ontario siano in grado di sviluppare, commercializzare e implementare nuove tecnologie in tutto il sistema sanitario”, ha dichiarato Dawn Gallagher Murphy, membro del Parlamento provinciale per Newmarket-Aurora. “Grazie a questo investimento, Piramal sarà in grado di trasformare le sue idee più innovative in soluzioni pronte per il mercato, creando al contempo posti di lavoro ben retribuiti e rafforzando la posizione dell’Ontario come polo globale per la biofabbricazione e le scienze della vita”. 

Lanciato per la prima volta nel 2024, il LSSUF, con una dotazione di 24 milioni di dollari, opera in sinergia con l’Health Innovation Pathway del governo per promuovere gli obiettivi della Fase 2 della Strategia per le Scienze della Vita dell’Ontario e rafforzare la posizione dell’Ontario come leader globale nell’innovazione sanitaria. Sulla scia del successo iniziale del fondo, il bilancio dell’Ontario del 2026 ha stanziato ulteriori 24 milioni di dollari a sostegno delle aziende dell’Ontario il cui lavoro accelererà l’adozione di tecnologie innovative nel sistema sanitario e supporterà la visione più ampia della provincia di fornire assistenza connessa e conveniente più vicina al domicilio dei pazienti. 

“Il settore delle scienze della vita dell’Ontario svolge un ruolo fondamentale nel supportare la scoperta e lo sviluppo di farmaci e tecnologie innovative, ed è per questo che il nostro governo è orgoglioso di sostenere le aziende locali nel portare i loro prodotti “Made in Ontario” a un livello superiore”, ha dichiarato Vic Fedeli, Ministro dello Sviluppo Economico, della Creazione di Posti di Lavoro e del Commercio. “Investendo in Piramal attraverso il Life Sciences Scale-Up Fund, stiamo potenziando la capacità produttiva interna della nostra provincia, consolidando ulteriormente la posizione dell’Ontario come giurisdizione leader per gli investimenti nel settore delle scienze della vita per le generazioni a venire”. 

Investendo nel sito di Aurora, il governo dell’Ontario rafforza la leadership dell’Ontario nel settore delle scienze della vita e aiuta PPS a portare le tecnologie di nuova generazione ai pazienti di tutto il mondo. 

Informazioni su Piramal Pharma Solutions 

Piramal Pharma Solutions (PPS) è un’organizzazione di sviluppo e produzione a contratto (CDMO) che offre soluzioni di sviluppo e produzione end-to-end per l’intero ciclo di vita dei farmaci. Serviamo i nostri clienti attraverso una rete globale integrata di strutture in Nord America, Europa e Asia. Questo ci consente di offrire una gamma completa di servizi, tra cui soluzioni per la scoperta di farmaci, servizi di sviluppo farmaceutico e di processo, forniture per sperimentazioni cliniche, fornitura commerciale di API (principi attivi farmaceutici) e forme farmaceutiche finite. Offriamo anche servizi specializzati come lo sviluppo e la produzione di API altamente potenti, anticorpi coniugati, riempimenti/confezionamenti in condizioni sterili, servizi e prodotti con l’utilizzo di peptidi nonché potenti prodotti farmaceutici solidi per somministrazione per via orale. PPS offre anche servizi di sviluppo e produzione di farmaci biologici tra cui vaccini e terapie geniche, grazie alla società controllata di Piramal Pharma Limited, ossia Yapan Bio Private Limited. 

Per maggiori informazioni: Piramal Pharma Solutions | LinkedIn| Facebook | X
 

Informazioni su Piramal Pharma Limited 

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offre un portafoglio di prodotti e servizi differenziati attraverso i suoi 17 impianti di sviluppo e produzione a livello mondiale e una rete globale di distribuzione in più di 100 Paesi. PPL include Piramal Pharma Solutions (PPS), un’azienda integrata di sviluppo e produzione a contratto, Piramal Critical Care (PCC), un’azienda di farmaci generici complessi per ospedali e la divisione Piramal Consumer Healthcare, che vende prodotti da banco e per il wellness. Inoltre, una delle aziende consociate di PPL, Abbvie Therapeutics India Private Limited, una joint venture tra Abbvie e PPL, è emersa come uno dei leader di mercato nell’ambito delle terapie oftalmologiche nel mercato farmaceutico indiano. 

Per maggiori informazioni: Piramal Pharma | LinkedIn
 

View original content to download multimedia:https://www.prnewswire.com/it/comunicati-stampa/lontario-investe-1-7-milioni-di-dollari-per-promuovere-linnovazione-nel-settore-delle-scienze-della-vita-presso-lo-stabilimento-di-aurora-di-piramal-pharma-302894949.html
 

Copyright 2026 PR Newswire. All Rights Reserved. 

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE: Immediapress è un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. L’Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi

—

immediapress/pr-newswire

FIRENZE – L’Europa prova a costruire una propria infrastruttura dei pagamenti capace, progressivamente, di rappresentare una vera alternativa continentale al predominio di Visa e Mastercard.

La novità arriva oggi (30 settembre) cinque grandi sistemi europei hanno annunciato la costituzione della European Network for Payments (Enp), una nuova società con sede a Madrid nata per collegare tra loro piattaforme di pagamento che complessivamente raggiungono circa 130 milioni di utenti in 13 Paesi europei.

A fondarla sono l’italiana Bancomat, la spagnola Bizum, Epi Company con il sistema Wero, la portoghese Sibs con Mb Way e la nordica Vipps MobilePay. I cinque fondatori saranno azionisti paritari della nuova società.

Il progetto parte da un principio differente rispetto a quello dei tradizionali circuiti internazionali: non creare necessariamente una nuova carta europea da mettere nel portafoglio, ma fare comunicare tra loro i sistemi di pagamento già utilizzati nei diversi Paesi.

Un cliente italiano potrà quindi continuare a utilizzare bancomat, uno spagnolo Bizum e un utente dei Paesi nei quali opera Wero continuare a utilizzare il proprio servizio. Dietro le diverse applicazioni, Enp dovrà costruire il livello tecnologico e operativo che consentirà ai sistemi di dialogare tra loro.

Il modello sarà basato anche sui pagamenti istantanei account-to-account, cioè trasferimenti direttamente da conto a conto attraverso infrastrutture europee. Ogni sistema conserverà il proprio marchio e la propria esperienza per l’utente.  Ed è proprio qui che si trova la parte più importante della sfida a Visa e Mastercard.

Oggi gran parte dei pagamenti elettronici effettuati dagli europei passa infatti attraverso infrastrutture appartenenti a gruppi extraeuropei. La creazione di una rete interoperabile continentale punta a consentire che una quota crescente delle transazioni possa essere gestita attraverso operatori e infrastrutture europee. Reuters colloca esplicitamente la nascita di ENP nel percorso intrapreso dall’Europa per ridurre la propria dipendenza dai due giganti americani.

Prima i trasferimenti tra persone, poi negozi ed e-commerce

Il progetto procederà per fasi. Il primo obiettivo sarà rendere interoperabili i pagamenti P2P, quelli effettuati direttamente tra persone. Successivamente la rete verrà estesa agli acquisti online e ai pagamenti effettuati nei negozi attraverso i Pos.  Non si parte, però, soltanto da un progetto sulla carta. Ad aprile Bancomat, Epi e Sibs-Mb Way hanno già completato con successo una sperimentazione tecnica che ha dimostrato la possibilità di effettuare pagamenti transfrontalieri nei negozi utilizzando Qr code e le rispettive applicazioni.

Durante il test, utenti delle diverse piattaforme hanno potuto effettuare pagamenti presso commercianti collegati agli altri sistemi. Il progetto ha visto anche il supporto operativo di istituzioni finanziarie come Intesa Sanpaolo e La Banque Postale.

La roadmap annunciata in primavera prevedeva i pagamenti P2P transfrontalieri nel 2026 e l’espansione verso e-commerce e POS nel 2027, compresi successivamente i pagamenti contactless Nfc.

L’Italia entra dalla porta principale con Bancomat

Per l’Italia la costituzione della nuova rete assume un valore particolare perché Bancomat entra direttamente tra i cinque fondatori. Il sistema italiano diventa quindi uno degli elementi attraverso i quali costruire la futura interoperabilità europea, insieme alle piattaforme già fortemente radicate nei rispettivi mercati nazionali. I sistemi che partecipano all’iniziativa raggiungono complessivamente circa 130 milioni di utenti in 13 Paesi, una base che rappresenta approssimativamente il 72 per cento della popolazione dell’Unione europea e della Norvegia.
Il vantaggio della strategia è proprio quello di non partire da zero: invece di convincere milioni di cittadini europei ad abbandonare immediatamente gli strumenti che già utilizzano, Enp punta a collegarli.

Wero intanto cresce in Europa

Parallelamente sta avanzando anche Wero, il portafoglio digitale sviluppato dalla European Payments Initiative.
A settembre il servizio è entrato nella fase finale della migrazione in Lussemburgo e la sua presenza si sta consolidando anche in Francia, Germania, Belgio e Paesi Bassi. La neobank bunq, ad esempio, ha recentemente completato l’attivazione di Wero per pagamenti tra persone e acquisti online nei quattro mercati.

La costituzione di Enp permette adesso di andare oltre il singolo progetto e di collegare Wero alle altre grandi soluzioni nazionali europee.
Una questione anche di sovranità economica

Dietro la partita tecnologica esiste infatti un tema strategico: chi controlla le infrastrutture attraverso le quali passa il denaro degli europei.
La crescente digitalizzazione dei pagamenti ha trasformato questi sistemi in infrastrutture essenziali dell’economia. Ridurre la dipendenza da operatori esterni significa, nelle intenzioni dei promotori, aumentare resilienza e autonomia del sistema europeo.

Il progetto privato si sviluppa inoltre parallelamente al percorso dell’euro digitale, che rappresenta però qualcosa di profondamente diverso: l’euro digitale sarebbe moneta di banca centrale emessa dall’Eurosistema, mentre ENP è una rete privata destinata a collegare sistemi di pagamento esistenti. Reuters riferisce che la nuova infrastruttura considera il futuro euro digitale potenzialmente integrabile nel proprio ecosistema.

La sfida a Visa e Mastercard, dunque, non significa che le carte americane siano destinate a scomparire né che ENP possa sostituirle nel breve periodo. Per arrivare a un’alternativa realmente comparabile saranno determinanti la diffusione presso i commercianti, l’adesione delle banche, l’estensione geografica e soprattutto la capacità di rendere i pagamenti europei altrettanto semplici e universali. Ma il passaggio del 30 settembre segna comunque un cambio di fase.

Dopo accordi, memorandum e sperimentazioni, Bancomat, Bizum, Wero, Mb Way e Vipps MobilePay mettono adesso una società comune dietro il progetto.

E per l’Europa dei pagamenti la domanda non è più soltanto se sia possibile costruire un’alternativa ai grandi circuiti internazionali. Da oggi la partita diventa capire quanto velocemente la nuova rete riuscirà a trasformarsi in un sistema utilizzabile quotidianamente da cittadini e imprese europee.

REDAZIONE

In breve tempo si sono precipitate sul posto una pattuglia dei carabinieri e un’ambulanza, che ha poi trasportato il giovane presso l’ospedale san Giuseppe di Empoli, in codice rosso, su una barella spinale per massima sicurezza. Il ragazzo non è in pericolo di vita, ma ha riportato diverse contusioni e lamenta ancora dolori agli arti inferiori.

PRESS RELEASE 

Bloomberg (THEON:NA) / Reuters (THEON.AS) 

30 September 2026 – Theon International Plc (THEON)  is pleased to announce it has been awarded various contracts for a total value of c.€50 million from European and Middle Eastern countries, with deliveries expected to commence this year. 

More specifically, Theon received the notification of award for the supply of its NYX night vision goggles and the ORION fused goggles to a European NATO Member state. This is the first major contract award for the ORION fused goggles from a western European end user, which is a significant step in the context of the THEON NEXT initiative to develop a European, fully interconnected future soldier vision system. 

Alongside the above, further orders have been received by KAPPA (100% owned by THEON) for various land and sea applications for a high single-digit million amount in total. 

Remaining orders reflecting a mix of man portable products. As we enter Q4 2026, the reprioritization towards land forces equipment anticipated by THEON earlier this year is already materialising, with THEON being selected across various projects. 

These orders further reinforce THEON’s leadership position in the evolving soldier modernisation era, and we continue to expect demand to accelerate in Q4 this year and into early 2027. 

Philippe Mennicken, Deputy CEO and Business Development Director of THEON stated: “We are pleased to see demand indicators across the board for the coming periods to point in the right direction as shown by the first batch of new orders and as already advised on reprioritisation in progress. With THEON’s selection across several other higher-value contracts and options, we expect to deliver strong last quarter 2026/first quarter 2027 (depending on approval processes by several governments) order intake, but like always we continue to remain conservative in our approach. Last, but not least, we are also pleased that our Business Development & R&D integration activities for the recent investments and acquisitions continue, especially for gimbals and air defence systems. While full operational integration can only commence following the receipt of required regulatory approvals, THEON has already commenced offering an integrated electro-optical platform globally, through these initial integration activities. “ 

For inquiries, please contact: 

About THEON GROUP 

THEON GROUP of companies develops and manufactures cutting-edge night vision and thermal imaging systems for Defense and Security applications with a global footprint. THEON GROUP started its operations in 1997 from Greece and today occupies a leading role in the sector thanks to its international presence through subsidiaries and production facilities in Greece, Cyprus, Germany, the Baltics, the United States, the Gulf States, Switzerland, Denmark, Belgium, Singapore and South Korea. THEON GROUP has more than 300,000 systems in service with Armed and Special Forces in 73 countries around the world, 26 of which are NATO countries. ΤΗΕΟΝ ΙΝΤΕRNATIONAL PLC has been listed on Euronext Amsterdam (AMS: THEON) since February 2024.www.theon.com
 

Attachment
 

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE: Immediapress è un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. L’Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi

—

immediapress/globenewswire

Le prime giornate di Serie B offrono spunti interessanti non solo sulla classifica, ma anche sull’efficacia offensiva delle squadre. Analizzando il rapporto tra tiri e gol realizzati e il rendimento nei due tempi di gioco emergono differenze marcate, dai record realizzativi dell’Arezzo nella ripresa alle difficoltà sotto porta della Carrarese.

La precisione offensiva in Serie B: Südtirol in vetta, Carrarese in affanno

Per la statistica relativa alla ripartizione dei tiri e alla percentuale di realizzazione, al primo posto figura il Südtirol, che con 63 tiri ha trovato 9 gol, vantando una percentuale del 14,3%.

A metà classifica troviamo Pisa e Arezzo, rispettivamente con il 7,5% (i nerazzurri) e il 6,7% (gli amaranto). Poco più giù c’è l’Empoli con il 5,6%, mentre in ultima posizione chiude la Carrarese con ben 94 tiri, appena 2 gol segnati e una percentuale del 2,1%. Tra le squadre che tirano di meno, in penultima posizione figura l’Empoli con 71 tiri e appena 4 gol realizzati, mentre a chiudere la classifica generale dei tiri c’è il Südtirol.

L’andamento dei gol nei due tempi di gioco

Il Pisa, insieme a Modena, Vicenza e Cremonese, è la squadra ad aver segnato più gol nella prima frazione di gioco (4). L’Empoli è invece la squadra che ne ha realizzati meno (0), insieme ad Avellino e Südtirol.

La Carrarese è a quota 1, al pari di Benevento, Mantova e Palermo; l’Arezzo a quota 2 con Cesena, Hellas Verona e Ascoli. Chiudono questo gruppo a quota 3 Padova, Virtus Entella, Sampdoria, Juve Stabia e Catanzaro.

Nella seconda frazione la distribuzione dei gol cambia radicalmente. In prima posizione assoluta figura l’Arezzo con ben 9 reti messe a referto.

A quota 6 troviamo l’Empoli, accompagnato da Avellino, Vicenza e Catanzaro, mentre a quota 5 ci sono Carrarese e Hellas Verona. A quota 4 figurano Palermo, Mantova, Benevento e Sampdoria, e a quota 3 Juve Stabia, Virtus Entella e Padova. A chiudere la classifica della ripresa c’è il Modena con 0 gol segnati; subito dopo, a quota 2, troviamo il Pisa insieme a Cremonese, Ascoli e Südtirol.

La tenuta difensiva nei due tempi

Nella classifica dei gol subiti, il Pisa è la squadra che, insieme a Modena, Cremonese e Vicenza, ha subito più reti nella prima frazione di gioco (4). L’Empoli, dal canto suo, è la formazione che ha incassato meno gol nei primi quarantacinque minuti (0), insieme ad Avellino e Südtirol. La Carrarese è a quota 1, al pari di Benevento, Mantova e Palermo; l’Arezzo a quota 2 con Ascoli, Hellas Verona e Cesena.

Nella ripresa, la classifica dei gol subiti vede l’Arezzo a quota 9, seguito a quota 6 dall’Empoli, accompagnato da Avellino, Lane Rossi Vicenza e Catanzaro. A quota 5 figurano Hellas Verona e Carrarese. Il Modena chiude la graduatoria con 0 gol subiti nella ripresa, subito prima del Pisa a quota 2, insieme a Südtirol, Ascoli e Cremonese.

Gioco aereo e impiego delle rose

Nella classifica dei gol subiti, il Pisa è la squadra che, insieme a Modena, Cremonese e Vicenza, ha subito più reti nella prima frazione di gioco (4). L’Empoli, dal canto suo, è la formazione che ha incassato meno gol nei primi quarantacinque minuti (0), insieme ad Avellino e Südtirol. La Carrarese è a quota 1, al pari di Benevento, Mantova e Palermo; l’Arezzo a quota 2 con Ascoli, Hellas Verona e Cesena.

Nella ripresa, la classifica dei gol subiti vede l’Arezzo a quota 9, seguito a quota 6 dall’Empoli, accompagnato da Avellino, Lane Rossi Vicenza e Catanzaro. A quota 5 figurano Hellas Verona e Carrarese. Il Modena chiude la graduatoria con 0 gol subiti nella ripresa, subito prima del Pisa a quota 2, insieme a Südtirol, Ascoli e Cremonese.

Davide Caruso

HONG KONG SAR – Media OutReach Newswire – 29 September 2026 – Hong Kong Science and Technology Parks Corporation (HKSTP), in partnership with German Industry and Commerce (GIC) and ADVANTAGE AUSTRIA, and supported by the Innovation, Technology and Industry Bureau, InvestHK and HKETO Berlin, led a delegation of eight Hong Kong Science Park companies to Germany and Austria from 21 to 25 September 2026 for a focused programme of business matching, ecosystem exchange and institutional engagement across Munich, Vienna and Graz. Bringing together government, industry, academia and innovation ecosystem partners, the mission deepened engagement with leading stakeholders, created new opportunities for cross-border collaboration and commercialisation in artificial intelligence (AI), new industralisation, and smart city, and reinforced Hong Kong’s role as a preferred platform for innovation exchange between Europe and Asia. 

The delegation marked a major step forward in HKSTP’s growing engagement in Central Europe. As HKSTP’s first market-focused mission to Germany, Europe’s largest AI market and a leading enterprise technology hub, it built on earlier collaboration with ADVANTAGE AUSTRIA, including GO AUSTRIA Spring 2025 and 2026 and the renowned ViennaUP Festival, as well as more recent joint efforts with partners in Germany and Austria under Global Connect and the Global Innovation Exchange. The ongoing efforts created practical pathways for Hong Kong companies to explore partnerships, validate demand and expand into key European markets. 

A key highlight was HKSTP’s participation in the Applied Artificial Intelligence Conference 2026 (AAIC) in Vienna, Austria, to connect with key industry partners and investors for potential business collaboration. Professor Sun Dong, Secretary for Innovation, Technology and Industry, delivered a speech titled “AAIC-Talk: Applied AI in Hong Kong and the Greater Bay Area: Innovation, Industrial Transformation and Opportunities for Collaboration with Austria”at theAustria’s flagship international AI business conference.He shared Hong Kong has elevated AI into a core industry and is emerging as one of the world’s most dynamic innovation and technology (I&T) centres. He also invited Austria to partner in shaping AI’s next chapter, and highlighting opportunities for collaboration between Hong Kong, the Greater Bay Area and Austria. During the Conference, Professor Sun had a brief exchange with park companies from the delegation participating in the Conference to learn about their innovative solutions. 

Mr Eric Or, Chief Ecosystem Development Officer of HKSTP, said, “HKSTP is committed to helping innovators scale beyond borders. Our inaugural delegation to Germany and the continuous connection with Austria highlights the value of strategic international engagement in opening doors for park companies to connect with leading industry, academic and investors in Europe. It also reflects Hong Kong’s unique role as a gateway for cross-border collaboration, underpinned by its distinct strengths as a super-connector and super value-adder. As HKSTP continues to expand its global outreach to further strengthen Hong Kong’s innovation links with global markets, and reinforce the city’s position as an international innovation and technology hub.” 

The delegation began in Munich, focusing on Germany’s industrial AI and enterprise innovation ecosystem, and engaging institutions including Chamber of commerce and industry for Munich and upper Bavaria (IHK), Siemens AI Lab, and the European Union’s top Technical University of Munich (TUM). Discussions centred on industrial AI, advanced manufacturing, technology translation and cross-border collaboration. The high potential tech firms continued the week-long journey in Vienna and Graz, connected with leading Austrian research, industry and innovation organisations, including the leading Graz University of Technology (TU Graz), Austrian Institute of Technology and more. 

Highlighted innovations from the delegation: 

Together, these engagements in Germany and Austria deepened HKSTP’s ties with the regions’ innovation ecosystem and opened new opportunities for collaboration in applied AI, robotics, smart production and commercialisation between Hong Kong and Europe. 

Appendix: List of park companies in the HKSTP’s delegation
 

Hong Kong Science and Technology Parks Corporation
 

Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 and has built a proven foundation as Hong Kong’s leading innovation and technology (I&T) ecosystem. Established for 25 years, HKSTP is supporting 14 unicorns, has nurtured more than 17,000 research professionals and built a community of over 2,600 technology companies from 26 countries and regions across four strategic pillars: Life and Health Technology, AI and Robotics, Microelectronics and Advanced Manufacturing, and GreenTech and New Energy. 

As an ecosystem orchestrator, HKSTP provides end-to-end support to attract and nurture talent, accelerate commercialisation and help technology ventures scale. Its innovation infrastructure spans over 240 hectares covering Hong Kong Science Park in Pak Shek Kok, three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long, and InnoCentre in Kowloon Tong, advancing Hong Kong’s vision for new industrialisation and smart manufacturing. 

Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen, strengthens cross-border collaboration by connecting Hong Kong, the Chinese Mainland and global innovation networks and propels Chinese innovators onto the world stage, while also delivering comprehensive GBA landing support to accelerate cross-border success for local and international ventures. 

As HKSTP enters its next chapter with strong foundations, it continues to deepen impact, elevate quality and create value for innovators. As an ecosystem built to lead change, HKSTP is empowering Hong Kong to define what comes next in innovation, growth and opportunity. 

More information about HKSTP is available at www.hkstp.org. 

Contatti:
Immediapress
comunicati@immediapress.it

Media contact: Angela LauTel: +852 6535 7611Email: angela.lau@hkstp.org 

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE

Responsabilità editoriale di Immediapress

—

immediapress

CONSHOHOCKEN, Pa., Sept. 30, 2026 /PRNewswire/ — Suvoda, a global clinical trial technology company, today announced a new release of important advancements since unifying the market-leading Suvoda and Greenphire products on one platform. Innovations in AI and new product functionality are expanding the platform’s capabilities, reducing manual work for users, and giving patients, sites, and sponsors more choices in how to engage with their trial technology worldwide. 

The Suvoda Platform connects technology and services across the mission-critical, time-sensitive moments in a clinical trial, so that sponsors, CROs, sites, and patients have the insight to make smarter decisions and the ease to move faster. It solves a longstanding challenge in clinical trials: study teams have had to stitch together technology that was never built to work together, with separate vendors, logins, and support teams in order to handle randomization, drug supply, questionnaire completion, payments, travel, and patient consent. Suvoda is turning that patchwork experience into a single platform the industry has not seen before. 

Advancements include: 

“This release shows what a platform-based and AI-enabled product suite makes possible. Sites can spend less time reconciling systems, patients can have an easier clinical trial experience wherever they are, and sponsors get faster answers to their important questions. I’m immensely proud of our teams. They have embraced a bold vision for the future and have brought it to life through innovative technology designed to make clinical trial work better for everyone involved,” said Jagath Wanninayake, CEO, Suvoda. 

Suvoda is a global clinical trial technology company with a market-leading, real-time software platform that empowers sponsors and CROs to make confident decisions and sites and patients to take calm, controlled action. Suvoda delivers interconnected, action-driven software solutions and industry-leading services and support, so that even in the most time-sensitive, mission-critical moments, life-changing studies keep moving forward. Suvoda recently merged with Greenphire, a leading provider of clinical trial financial management and patient support tools. To learn more, visit suvoda.com and follow Suvoda on LinkedIn. 

Media Contact:  

Robin Abadía, Director, External Communicationsmarketing@suvoda.com
 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/suvodas-latest-platform-release-creates-a-global-experience-across-study-data-patient-engagement-scheduling-payments-and-clinical-trial-operations-302890720.html
 

Copyright 2026 PR Newswire. All Rights Reserved. 

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE: Immediapress è un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. L’Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi

—

immediapress/pr-newswire

BARCELONA, Spain and DUBAI, UAE and LONDON, Sept. 30, 2026 /PRNewswire/ — Twelve months after a landmark Barca Mobile partnership, Zetexa—the global travel-technology firm behind an enterprise eSIM and journey-ancillaries platform—has confirmed a string of major European contract wins with consumer fintechs, neobanks, super-apps and online travel agencies. The company already works with partners in more than 50 countries, with deep coverage across the United Kingdom, Germany, France, Italy, Portugal, the Netherlands, Turkey, Belgium & Czech Republic. 

Zetexa’s B2B2C model embeds travel connectivity and airport services under the partner’s brand via one API—users buy, recharge and manage journeys inside the app they already trust. European buyers are moving straight into multi-year production rollouts. 

The stack is built for regulated, high-volume operators: enterprise APIs with SOC 2, VAPT, GDPR and PCI DSS, plus Kubernetes cloud infrastructure sized for heavy daily transaction loads. One eSIM covers 180+ countries with lifetime-valid profiles and continuous top-ups—no new SIM per trip. Partners design recharge journeys that pull travellers back for future travel. Packs are fully customisable by days, GB and limited or unlimited data, instead of forcing partners to resell a rigid supplier catalogue. Physical SIMs deliver the same feature set for devices without eSIM hardware. 

Premium levers include white-label “Your Brand” naming on the handset, and “Your App Always On”—when data runs out, the partner’s app stays live for recharge, bookings and support while other apps do not. Location insights show where users travel for real-time offers; SMS flags data usage. Unlike data-only eSIM vendors, Zetexa adds voice-plus-data calling packs in 70 countries, including a USA number on the native dialler for emergencies abroad. Local long-stay packs cover the US, Canada and the UK. The same API also sells global lounge, fast track and meet-and-greet. Support is 24×7, with an Arabic-speaking team in Egypt for bilingual European and Middle East corridors. 

“Europe’s largest fintechs and OTAs are choosing Zetexa because we deliver what only top-tier eSIM platforms can: enterprise security, one SIM across 180+ countries, fully custom packs, voice and data, and lounge and airport ancillaries—all in one API. Barcelona proved the model. This year’s European deals prove the scale,” said Srujan Yeleti, Co-Founder, Zetexa Global. 

European product, partnerships and BD teams planning 2026–27 roadmaps can request a technical and commercial briefing. 

Media / partnerships: partnerships@zetexa.com | www.zetexa.com
 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/zetexa-closes-wave-of-large-european-deals-a-year-after-barcelona-win-302894488.html
 

Copyright 2026 PR Newswire. All Rights Reserved. 

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE: Immediapress è un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. L’Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi

—

immediapress/pr-newswire

Acquisition extends Resonant’s European footprint and adds specialized calibration expertise, IOR/EOR reach, and partner depots to support the clinical trial lifecycle at global scale 

LEESBURG, Va., Sept. 30, 2026 /PRNewswire/ — Resonant Clinical Solutions (“Resonant”), a global clinical solutions partner serving life sciences organizations across the clinical supply chain and sample lifecycle, today announced that it has acquired Germany-based labfish rental solutions Gmbh (“Labfish”) and its U.S. and U.K. affiliates, which together provide end-to-end clinical and laboratory rental equipment and calibration solutions. The acquisition expands Resonant’s Equipment & Ancillaries (E&A) presence in Europe and strengthens its ability to support increasingly complex clinical trial programs around the world with high-demand, specialized capabilities. 

Based in Hamburg, Germany, Labfish offers a broad inventory of laboratory equipment for rent — including scales, freezers, refrigerators, infusion pumps, and monitors — alongside kitting, ancillary supplies, and industry-leading in-house calibration expertise. Labfish also provides Importer of Record (IOR)/Exporter of Record (EOR) and white-glove direct-to-patient logistics management, working with partner depots in Argentina, Israel, Turkey, and China to supply clinical trial sites in more than 70 countries. Originally founded in 2014, Labfish is ISO 9001-certified and operates one of the largest in-house calibration facilities serving clinical trials in Europe. 

“Incorporating Labfish into Resonant’s E&A business extends our presence in Europe and deepens our calibration and import/export services, further enhancing the world-class clinical trial solutions our customers depend on,” said Christophe Berthoux, Chief Executive Officer, Resonant Clinical Solutions. “This acquisition builds on the success of our Equipment & Ancillaries business to meet the rapidly evolving needs of our customers. The capabilities Labfish brings to Resonant advances our strategy to support more of the clinical journey at global scale.” 

Increasingly complex clinical trial programs demand specialized equipment, calibration, and logistics support that keep pace with evolving research protocols, workflows, and requirements. To meet this need, the Labfish acquisition complements Resonant’s existing E&A business, providing client partners with a robust offering and technical expertise in Europe as their development programs scale. 

“Joining Resonant allows our team to further grow the calibration expertise, warehouse network, and import/export and logistics services we’ve spent years developing, now with the capabilities to support more of the clinical trial journey,” said Martin Forster, Founder, Labfish. “We’re excited to bring our technical knowledge, strategic services, and valued customer relationships to Resonant.” 

Financial terms of the transaction were not disclosed. 

About Resonant Clinical SolutionsResonant Clinical Solutions is a global clinical solutions partner serving life sciences organizations across the clinical supply chain and sample lifecycle. Through its Biorepository, Kitting, and Equipment & Ancillaries businesses, Resonant helps customers manage complexity, reduce risk, and support critical clinical programs around the world. With more than 850 employees across the U.S., U.K., and Europe, Resonant manages more than 100 million research assets in storage, and has supported more than 2,500 clinical trials and facilitated more than 20,000 customer-site shipments. The company serves pharmaceutical and biotechnology companies, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and diagnostic and reference laboratories. 

Resonant’s mission is to empower its partners with comprehensive, global clinical supply chain and sample lifecycle solutions that remove complexity and enable them to focus on science and patients. For more information, visit resonantclinical.com. 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/resonant-clinical-solutions-expands-global-equipment–ancillaries-business-with-acquisition-of-labfish-302893240.html
 

Copyright 2026 PR Newswire. All Rights Reserved. 

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE: Immediapress è un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. L’Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi

—

immediapress/pr-newswire

BEIJING, Sept. 30, 2026 /PRNewswire/ — The 94th China International Medical Equipment Fair (CMEF) and concurrent events—including ICMD, covering medical device design and manufacturing; CRS, focusing on rehabilitation and assistive technology; CECN, dedicated to elderly care and nursing; and Healthy Lifestyle—will take place October 21–24 at the Capital International Exhibition & Convention Center in Beijing. Organized by Reed Sinopharm Exhibitions, the event will showcase innovations across the medical device value chain and promote international sourcing, technology exchange and commercial partnerships. 

Spanning about 170,000 square meters, CMEF and its concurrent events will bring together nearly 3,000 exhibitors from China and abroad. More than 120,000 professional visitors and nearly 10,000 overseas buyers are expected, along with close to 100 industry forums and networking activities. 

The event will cover medical imaging, in vitro diagnostics, operating room equipment, medical consumables, rehabilitation and senior care, home healthcare, pet health, medical aesthetics, and emergency response, connecting R&D and design with manufacturing, clinical use and commercialization. 

Specialized areas will spotlight emerging healthcare technologies. The Medical AI Frontier Zone will feature Chinese innovations in medical robotics, brain-computer interfaces, embodied AI, large-scale medical AI models, high-quality datasets, 5G applications and AI-enabled healthcare, as well as innovative drugs and medical devices. The International Zone will showcase products, technologies and solutions from around the world. 

Together, these exhibits will offer participants a single platform to track technology trends, identify relevant products and explore partnerships across the medical device value chain. 

WeSeries Connects International Buyers with Products and Suppliers 

Designed for international buyers, the WeSeries will support product discovery, supplier evaluation and targeted business meetings. 

At the WeTalk Stage, companies will present solutions in medical robotics, brain-computer interfaces, embodied AI, medical aesthetics, consumables, rehabilitation and assistive devices, and home medical equipment. The WeMatch Hub will provide one-on-one matchmaking between buyers and exhibitors. The International WeTour will offer customized itineraries with English-language guidance, product presentations, hands-on experiences and direct access to exhibitors. 

Beijing-Tianjin-Hebei Coordinated Innovation Pavilion Highlights the Regional Healthcare Ecosystem 

The Beijing-Tianjin-Hebei Coordinated Innovation Pavilion will highlight coordinated innovation and development across Beijing, Tianjin and Hebei, showcasing the region’s industrial resources, innovative companies and medical technology achievements. It will give international visitors a closer look at the region’s healthcare innovation ecosystem. 

Beyond the Great Wall, the Forbidden City and the Temple of Heaven, Beijing offers extensive medical and wellness services. The city has 11,994 medical institutions and 155 health and senior care centers. Fifty-two medical institutions have international departments, 156 provide foreign-language assistance, and 167 accept international bank cards. 

Ordinary passport holders from 50 countries covered by China’s unilateral visa-free policy may enter for business for up to 30 days. Eligible travelers with confirmed onward tickets may transit through Beijing under the 240-hour visa-free policy, making it easier to combine CMEF business with the city’s cultural and wellness offerings. 

For information and pre-registration, visit: 

CMEF English website: https://www.cmef.com.cn/en
 

Pre-registration: https://reg.reed-sinopharm.com/pc/#/login?id=5ddeaa7e26e9472bb78671da18937b6c&channelUuid=2499c9c3f61548e0a61fca4118a8ec3a
 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/the-94th-cmef-the-worlds-leading-medical-device-industry-event-set-to-open-in-beijing-oct-2124-302894134.html
 

Copyright 2026 PR Newswire. All Rights Reserved. 

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE: Immediapress è un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. L’Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi

—

immediapress/pr-newswire